Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$39.53−0.46 (-1.15%)
Close on Nov 13, 2026Market cap $28.55BP/E –Yield –
Roivant Sciences operating margin
Operating margin is operating income as a percentage of revenue.
Roivant Sciences's operating margin for the twelve months ending Sep 30, 2026 was -1358.1%. For fiscal 2025 it was -6235.7%, against -3453.3% the year before. The highest annual figure on record is 13746.9% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | -6235.7% | −2782.4 |
| FY2024 | Mar 31, 2025 | -3453.3% | −17200.2 |
| FY2023 | Mar 31, 2024 | 13746.9% | +16622.8 |
| FY2022 | Mar 31, 2023 | -2875.9% | −431.1 |
| FY2021 | Mar 31, 2022 | -2444.8% | +2055.7 |
| FY2020 | Mar 31, 2021 | -4500.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ3 2026 | Sep 30, 2026 | -763.2% | +18729.7 |
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | -25380.9% | −12250.9 |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | 16477.8% | +20242.2 |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | -16966.1% | −13923.5 |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | -19492.9% | −11856.8 |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | -13130.0% | −11850.5 |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | -3764.4% | −1471.3 |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | -3042.6% | −35991.2 |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | -7636.0% | −1772.8 |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | -1279.5% | −1.3 |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | -2293.1% | −2418.7 |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | 32948.6% | +35165.8 |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | -5863.2% | −3623.0 |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | -1278.3% | +5258.2 |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | 125.6% | +3018.4 |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | -2217.2% | −1206.5 |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | -2240.2% | +2653.1 |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | -6536.4% | −4540.5 |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | -2892.8% | +678.0 |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | -1010.7% | +3494.8 |
| Q2 FY2021CQ3 2021 | Sep 30, 2021 | -4893.3% | +6939.0 |
| Q1 FY2021CQ2 2021 | Jun 30, 2021 | -1996.0% | +5266.3 |
| Q4 FY2020CQ1 2021 | Mar 31, 2021 | -3570.8% | – |
| Q3 FY2020CQ4 2020 | Dec 31, 2020 | -4505.6% | – |
| Q2 FY2020CQ3 2020 | Sep 30, 2020 | -11832.3% | – |
| Q1 FY2020CQ2 2020 | Jun 30, 2020 | -7262.2% | – |
See a number that looks wrong?